Back to Top

Annemieke DeMaggio's blog

BCR-ABL inhibitor asciminib (ABL001) meets phase 3 primary endpoint in CML

Asciminib significantly improved the Molecular Response Rate at 24 wks vs bosutinib in previously treated CML (Novartis press release)

Tepotinib granted FDA priority review for METex14 NSCLC

FDA BTD and NDA filing based on data from ongoing phase 2 VISION study; no PDUFA date mentioned (EMD press release)


Subscribe to RSS - Annemieke DeMaggio's blog